Hydrochloric Acid

Hydrochloric Acid

SCHEMBL3468007

COc1cccc2c1CC[C@H](N)C2.Cl

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
DRD2 known ✓ P14416 11/20 0.97
DRD3 known ✓ P35462 9/20 0.97
ADRA1A known ✓ P35348 1/20 0.63
DRD4 known ✓ P21917 6/20 0.61
CHRM2 known ✓ P08172 1/20 0.60
CHRM1 known ✓ P11229 1/20 0.60
CHRM3 known ✓ P20309 1/20 0.60
MTNR1A P48039 1/20 0.55
MTNR1B P49286 1/20 0.55
PLAU P00749 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6824058 1.00 DRD2 (0.97) DRD2DRD3ADRA1ADRD4CHRM2
Hydrochloric Acid SCHEMBL6824054 1.00 DRD2 (0.97) DRD2DRD3ADRA1ADRD4CHRM2
Hydrochloric Acid SCHEMBL31672141 1.00 DRD2 (0.97) DRD2DRD3ADRA1ADRD4CHRM2
SCHEMBL43366 0.98 DRD2 (1.00) DRD2DRD3ADRA1ADRD4CHRM2
SCHEMBL895845 0.98 DRD2 (1.00) DRD2DRD3ADRA1ADRD4CHRM2
SCHEMBL895742 0.98 DRD2 (1.00) DRD2DRD3ADRA1ADRD4CHRM2
SCHEMBL29429678 0.98 DRD2 (1.00) DRD2DRD3ADRA1ADRD4CHRM2
SCHEMBL29547385 0.98 DRD2 (1.00) DRD2DRD3ADRA1ADRD4CHRM2
SCHEMBL9315535 0.89 DRD2 (0.82) DRD2DRD3ADRA1ADRD4CHRM2
Hydrochloric Acid SCHEMBL4208502 0.89 DRD2 (0.77) DRD2DRD3ADRA1ACHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9145353-B2 Method of preparing (S)-2-amino-5-methoxytetralin hydrochloride ANHUI KELONG INSTITUTE OF PHARMACEUTICAL (CN) 2015-09-29 US claimed
US-20140046095-A1 Method of Preparing (S)-2-amino-5-Methoxytetralin Hydrochloride ANHUI KELONG INSTITUTE OF PHARMACEUTICAL (CN) 2014-02-13 US claimed
US-20170305877-A1 Processes for the Preparation of Rotigotine and Intermediates Thereof APOTEX INC. (CA) 2017-10-26 US disclosed
US-20160297745-A1 ENDODONTIC POST SYSTEM APOTEX INC (CA) 2016-10-13 US disclosed
WO-2016044918-A1 PROCESSES FOR THE PREPARATION OF ROTIGOTINE AND INTERMEDIATES THEREOF APOTEX INC. (CA) 2016-03-31 WO disclosed
US-9145353-B2 Method of preparing (S)-2-amino-5-methoxytetralin hydrochloride ANHUI KELONG INSTITUTE OF PHARMACEUTICAL (CN) 2015-09-29 US disclosed
US-9145353-B2 Method of preparing (S)-2-amino-5-methoxytetralin hydrochloride ANHUI KELONG INSTITUTE OF PHARMACEUTICAL (CN) 2015-09-29 US disclosed
US-9145353-B2 Method of preparing (S)-2-amino-5-methoxytetralin hydrochloride ANHUI KELONG INSTITUTE OF PHARMACEUTICAL (CN) 2015-09-29 US disclosed
US-20140046095-A1 Method of Preparing (S)-2-amino-5-Methoxytetralin Hydrochloride ANHUI KELONG INSTITUTE OF PHARMACEUTICAL (CN) 2014-02-13 US disclosed
US-20140046095-A1 Method of Preparing (S)-2-amino-5-Methoxytetralin Hydrochloride ANHUI KELONG INSTITUTE OF PHARMACEUTICAL (CN) 2014-02-13 US disclosed
US-20140046095-A1 Method of Preparing (S)-2-amino-5-Methoxytetralin Hydrochloride ANHUI KELONG INSTITUTE OF PHARMACEUTICAL (CN) 2014-02-13 US disclosed
US-20110313176-A1 PROCESSES FOR PREPARING HIGHLY PURE ROTIGOTINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ACTAVIS GROUP PTC EHF (IS) 2011-12-22 US disclosed
WO-2010073124-A2 PROCESSES FOR PREPARING HIGHLY PURE ROTIGOTINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ACTAVIS GROUP PTC EHF (IS) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140046095-A1 Method of Preparing (S)-2-amino-5-Methoxytetralin Hydrochloride ADRB2, TPMT, TDO2 DRD2 44/4885DRD3 143/4885ADRA1A 10/4885
US-20170305877-A1 Processes for the Preparation of Rotigotine and Intermediates Thereof C1S, C1R, C3AR1 DRD2 119/4885DRD3 105/4885ADRA1A 675/4885
US-20160297745-A1 ENDODONTIC POST SYSTEM ABCB11, EXOC3, C1S DRD2 552/4885DRD3 125/4885ADRA1A 1397/4885
US-20110313176-A1 PROCESSES FOR PREPARING HIGHLY PURE ROTIGOTINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF MC4R, AVPR2, MC5R DRD2 100/4885DRD3 216/4885ADRA1A 169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.